These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11011806)

  • 1. Prophylaxis and treatment of deep-vein thrombosis.
    Breddin HK
    Semin Thromb Hemost; 2000; 26 Suppl 1():47-52. PubMed ID: 11011806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery.
    Breddin HK
    Semin Thromb Hemost; 1999; 25 Suppl 3():83-9. PubMed ID: 10549721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic therapy for the management of thrombosis: unfractionated heparin or low-molecular-weight heparin?
    Spyropoulos AC
    Clin Cornerstone; 2005; 7(4):39-48. PubMed ID: 16758651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unfractionated heparin and low-molecular-weight heparin for the initial treatment of acute venous thromboembolism.
    Prandoni P
    Haemostasis; 1998; 28 Suppl 3():85-90. PubMed ID: 10069766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
    Martineau P; Tawil N
    Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.
    Chapman TM; Goa KL
    Drugs; 2003; 63(21):2357-77. PubMed ID: 14524738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
    Heaton D; Pearce M
    Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
    Dolovich LR; Ginsberg JS; Douketis JD; Holbrook AM; Cheah G
    Arch Intern Med; 2000 Jan; 160(2):181-8. PubMed ID: 10647756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
    Haas S
    Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of thromboembolism in the outpatient setting.
    Agnelli G; Rossi R; Santamaria MG
    Semin Hematol; 2000 Jul; 37(3 Suppl 5):23-6. PubMed ID: 11055893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
    Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
    Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of venous thromboembolism: challenging the unfractionated heparin standard.
    Nutescu E; Singh-Khalsa M;
    Pharmacotherapy; 2004 Aug; 24(8 Pt 2):127S-131S. PubMed ID: 15334858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.